Supportive Care in Cancer

, Volume 16, Issue 2, pp 193–200

The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines

  • Matti Aapro
  • Ivo Abraham
  • Carsten Bokemeyer
  • Heinz Ludwig
  • Karen MacDonald
  • Pierre Soubeyran
  • Matthew Turner
Original Article

DOI: 10.1007/s00520-007-0311-2

Cite this article as:
Aapro, M., Abraham, I., Bokemeyer, C. et al. Support Care Cancer (2008) 16: 193. doi:10.1007/s00520-007-0311-2

Abstract

Goal

The benefit of supportive care with erythropoiesis-stimulating agents (ESAs) for patients with cancer-related anaemia is well known. However, the European Cancer Anaemia Survey (ECAS, data from 2001) showed that about 60% of cancer patients with anaemia do not receive any treatment. Since ECAS, evidence-based guidelines have provided recommendations for ESA use, but it is not known to what extent current treatment patterns follow these guidelines. To address this issue, the Anaemia Cancer Treatment (A.C.T.) study was initiated. The background to the development of the A.C.T. study and study methodology are described.

Materials and methods

The A.C.T. study is a global, retrospective, pharmacoepidemiologic study of at least 2,560 medical records of anaemic patients with cancer who were previously treated with an ESA from a minimum of 186 centres. Records from patients aged greater than or equal to 18 years with a diagnosis of solid tumour or myeloma or lymphoma and who were started on ESAs 3–12 months before inclusion and followed for 8–10 weeks will be eligible. Factors associated with ESA non-responsiveness will also be evaluated.

Main results

Completion of the European phase of the study is anticipated in late 2007 with the rest of the world closing in late 2007 or early 2008. Publication of findings is anticipated in 2008.

Conclusions

By examining the extent to which anaemia management in clinical practice is congruent with best practice guidelines, the A.C.T. study will provide a further foundation for the development of evidence-based supportive cancer care.

Keywords

Anaemia Cancer Retrospective Erythropoiesis-stimulating agent 

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Matti Aapro
    • 1
  • Ivo Abraham
    • 2
    • 3
  • Carsten Bokemeyer
    • 4
  • Heinz Ludwig
    • 5
  • Karen MacDonald
    • 2
  • Pierre Soubeyran
    • 6
  • Matthew Turner
    • 7
  1. 1.Multidisciplinary Oncology InstituteGenolierSwitzerland
  2. 2.Matrix45EarlysvilleUSA
  3. 3.University of Pennsylvania Center for Health Outcomes and Policy Research and Leonard Davis Institute of Health EconomicsPhiladelphiaUSA
  4. 4.University Medical Centre EppendorfHamburgGermany
  5. 5.Department of Medicine ICentre for Oncology and HaematologyViennaAustria
  6. 6.Institut BergoniéComprehensive Cancer CentreBordeauxFrance
  7. 7.Roche Products LtdWelwyn Garden CityUK

Personalised recommendations